Skip to main content

Table 2 Measurements secondary objectives: psychopathology and cost effectiveness

From: A multi-site single blind clinical study to compare the effects of prolonged exposure, eye movement desensitization and reprocessing and waiting list on patients with a current diagnosis of psychosis and co morbid post traumatic stress disorder: study protocol for the randomized controlled trial Treating Trauma in Psychosis

Secondary outcome

MeasurementInterview(i),self-report(s)

T0 baseline

T1 midtreatment

T2 posttreatment

T6 FU 6 month

T12 FU 12 months

Paranoid thinking

GPTS (s)

x

 

x

x

x

Verbal hallucinations

AHRS (i)

x

 

x

x

x

Delusions

DRS (i)

x

 

x

x

x

Basic assumptions

AVH-BAS (s)

x

x

x

x

x

Verbal hallucinations

ESM (s, psymate)

x

 

x

  

Depression

BDI-II (s)

x

 

x

x

x

Social functioning

PSP (i)

x

 

x

x

x

Posttrauma cognitions

PTCI (s)

x

x

x

x

x

Remission

SCI-SR (i)

x

 

x

x

x

Care consumption

TiC-P (s)

x

 

x

x

x

Health outcome

EQ-5D (s)

x

 

x

x

x

  1. AHRS Auditory Hallucination Rating Scale, AVH-BAS Auditory Verbal Hallucinations – Basic Assumptions Scale, BDI-II Beck Depression Inventory - II, DRS Delusion Rating Scale, ESM Experience Sampling Method, EQ-5D™ EuroQol - 5 dimensions GPTS Green ParanoiaThought Scale, PSP Social Performance Scale PTCI Posttraumatic Cognitions Inventory, SCI-SR Structured Clinical Interview for Symptoms of Remission for the PANSS, TiC-P Trimbos/iMTA questionnaire for Costs associated with Psychiatric Illness - short version.